ALKEON CAPITAL MANAGEMENT LLC

Q3 2022 13F-HR Detailed Holdings

Location
New York, NY
Holdings as of
9/30/2022
Date filed
11/10/2022
Form type
13F-HR
Num holdings
251
Total value ($000)
$30,929,413
Net value change ($000)
-6,224,659 (-16.8%)
New positions
2
Sold out positions
10
Turnover %
3.3%
Sector allocation + QoQ delta (equities-only)

Holdings broken out by other managers reported in the original SEC filing. View aggregated holdings

You are on the SEC detailed breakdown page. Rows are shown as reported in the filing (including other manager, discretion, and voting authority fields), and are not merged like the standard holdings view. Switch to aggregated holdings.

Snapshot: Change Analysis

Compared to Q2 2022
Methodology: sector metrics are equities-only; instrument mix chart is ex-options; options exposure is shown separately. Why this matters.
Top Adds (Value $000, Stocks/ETFs)
UBER 112,088 67.4%
BABA 104,365 137.7%
BILL 101,757 NEW
MELI 91,643 32.7%
AKRO 82,919 334.9%
EXPE 72,209 36.5%
ZM 65,372 87.0%
SRPT 49,435 57.0%
RYTM 35,548 571.1%
TSM 34,888 10.9%
Top Reduces (Value $000, Stocks/ETFs)
KLAC -176,916 -31.7%
QCOM -173,882 -32.1%
LRCX -166,655 -35.2%
META -164,258 -25.2%
GOOGL -137,280 -15.2%
ADI -114,616 -26.0%
BURL -113,130 -100.0%
AMT -111,253 -34.6%
DASH -102,812 -100.0%
SHOP -102,381 -70.0%
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000): 16,420,784 (53.1% of total reported value)
How this table is calculated: SEC VALUE ($000) is used as reported. For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received. Column % is bucket-based: non-options share is calculated inside non-option total, options share is calculated inside options total. Details.
Filter:
Instrument:
Issuer Name Ticker Sector Industry Class History Value ($000) % Shares Shares Δ Shares Δ% Value Δ ($000) Value Δ% Principal Option Type Discretion Other Manager Sole Shared None

Other Managers

Num Name File Number
1 OPPENHEIMER ASSET MANAGEMENT INC. 028-10748